Disease monitoring in inflammatory bowel disease

Chang, Shannon; Malter, Lisa; Hudesman, David

doi:10.3748/wjg.v21.i40.11246

Cited by 153 publications

(130 citation statements)

References 111 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Crohn' s disease (CD) and ulcerative colitis (UC) may affect different digestive tract segments, having different clinical manifestations, prognoses, and treatments. However, up to 30% of patients with IBD are either misdiagnosed or a proper diagnosis cannot be made even with the current available armamentarium [1,2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Tefas

Ciobanu

Tanţău

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are conditions that still pose significant problems. A third of the patients are either misdiagnosed or a proper diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) cannot be made. We need new biomarkers, so that we can offer patients the best treatment and keep the disease in an inactive state for as long as possible. Alterations in metabolic profiles have been incriminated in the pathophysiology of IBD. The aim of the present study was to identify molecules that could serve as biomarkers for a positive diagnosis of IBD as well as to discriminate UC from colonic CD. Twenty-two patients with active colonic IBD (UC = 17, CD = 5) and 24 age- and gender-matched healthy controls were enrolled. Plasma lipid and metabolic profiles were quantified using ultra-high performance liquid chromatography combined with mass spectrometry. Univariate and multivariate statistical tests were employed. Six lipid species and seven metabolites were significantly altered in IBD compared to healthy controls, with the majority belonging to glycerophospholipid, linoleic acid, and sphingolipid metabolisms. Five lipid species and only one metabolite were significantly increased in UC compared to CD. This preliminary study suggests that lipid and metabolic profiling of serum can become diagnostic tools for IBD. In addition, they can be used to differentiate between CD and UC.

show abstract

Section: Introductionmentioning

confidence: 99%

“…New biomarkers and techniques that enable a better diagnosis of IBD are expected. The current biomarkers -erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin or fecal lactoferrin -each has its limitations, the most important being the lack of specificity [2].…”

Section: Introductionmentioning

confidence: 99%

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Tefas

Ciobanu

Tanţău

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…However, for unknown mechanism, it correlates significantly with CD but not UC [42,43] while high-sensitivity C-reactive protein (hs-CRP) and β2-microglublin correlate with histology scores of UC [44]. To summarize, CRP can be falsely low despite active mucosal inflammation while it is more reliable in transmural inflammation [45].…”

Section: C-reactive Protein (Crp)mentioning

confidence: 99%

Bio-Markers of Inflammatory Bowel Disease: Past, Present, and Future

Bahgat¹

2017

Austin J Gastroenterol

View full text Add to dashboard Cite

Ulcerative colitis (UC) and Crohn's disease (CD) exemplify the two main arms of the spectrum of an idiopathic chronic disease known as inflammatory bowel disease (IBD). To date, this disease remained a puzzling dilemma in many aspects; including difficulties in its etiology/pathogenesis, diagnosis, severity assessment, treatment and outcomes/complications. Physicians usually get the diagnosis of IBD through a combination of clinical features, laboratory tests, radiology, as well as the invasive technique of endoscopy/biopsy. In spite of these efforts, the definite diagnosis can't be established in a significant cohort of cases. This paved the way to searching for laboratory biomarkers that are noninvasive, reproducible, rapid and relatively cheap than other modalities. Unfortunately, we're still far from these ideal biomarkers. Some biomarkers are already being used in daily practice including C-reactive protein (CRP) and fecal calprotectin while others are still in need for confirmation before being applied in clinical practice. In this review article, the authors are going to discuss the past, present, and future utility of biomarkers in IBD. This article aims at highlighting the uses and limitations of all possible current and novel biomarkers in every aspect of the disease from predisposition to prognosis.

show abstract

“…Serum CRP and fecal calprotectin are valuable monitoring tools in this context. [64][65][66] In the case of switching between different anti-TNF agents, it is known that patients who developed ADA to IFX more often develop ADA to ADL versus anti-TNF naïve patients. [67,68] Identification of these patients on beforehand is not possible yet, but there is evidence that immunogenicity to IFX is associated with HLA-DRB1.…”

Section: Combination Therapymentioning

confidence: 99%

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease

Strik

Bots

D’Haens

et al. 2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of anti-TNF therapy is complicated by loss of response. In order to maintain remission, adequate serum levels are required. Hence, therapeutic drug monitoring (TDM) is important in order to optimize serum drug levels, especially in patients with loss of response to these agents. Optimization of anti-TNF therapy by applying TDM enables clinicians to regain response to TNF blockers in a significant proportion of patients. It is important to use anti-TNF agents in their most optimal way, since these therapeutic agents are expensive and the medical options after failing anti-TNF therapy are limited. Here, we will discuss how to optimize treatment with anti-TNF agents in IBD patients in order to improve treatment efficacy, prevent anti-drug antibody formation, reduce side effects, discontinue unnecessary treatment and manage costs. ARTICLE HISTORY

show abstract

Disease monitoring in inflammatory bowel disease

Cited by 153 publications

References 111 publications

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Bio-Markers of Inflammatory Bowel Disease: Past, Present, and Future

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease

Contact Info

Product

Resources

About